alexa HIV DNA Remaining Not Detectable Two Years After Tat Oyi Vaccination In HIV Infected Volunteers Under CART | 67534
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Erwann Loret
Aix Marseille University, France
Posters & Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-058
Abstract
A synthetic vaccine targeting the HIV Tat protein was tested on HIV infected volunteers under antiretroviral treatment (cART) at Marseille. BIOSANTECH is the sponsor of this monocentric clinical trial divided in a phase I/IIa and in a phase IIb. The protocol, based on the hypothesis that neutralizing antibodies against Tat may contribute to eliminate HIV infected cells, was authorized by the French drug administration (ANSM) on January 24th, 2013. Long term HIV infected volunteers (n=48) were randomized in four groups having at M0, M1 and M2 double blinded intradermal injections respectively with 0, 11, 33 or 99 μg of a synthetic protein called as Tat Oyi in a phosphate buffer complemented with NaCl (9 g/l) without adjuvant. The result of Phase I/IIa revealed that the Tat Oyi vaccine was safe and was statistically effective at lowering the extent of HIV RNA (Mann and Whitney test, p=0.07, 95% confidence interval) following a cART interruption from M5 to M6 (Loret et al., 2016). Follow up of volunteers showed that HIV DNA remains no longer detectable at M24 in those who got the vaccine (Figure 1). HIV DNA not detectable for a long period of time is never observed in HIV infected patients under cART. This is the first step toward HIV eradication reached by the Berlin patients in 2009. The second step is a decrease of antibodies against HIV (retro seroconversion) that the Berlin patient reached in 2012. A phase IIb will begin soon on volunteers who participated to phase I/IIa. The main outcome is that Tat Oyi vaccinated volunteers who are HIV DNA not detectable, with a rétroséroconversion, can stop cART and remain HIV RNA and HIV DNA not detectable. In that case, the Tat Oyi vaccine would allow HIV infected patient to reach a functional cure.
Biography

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version